{
  "id": "515de748298dcd4e51000023",
  "type": "list",
  "question": "List all approved indications for Glivec",
  "ideal_answer": "CML - blast crisis, in accelerated phase, and in chronic phase after interferon failure or intolerance.  Glivec received orphan drug status from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development on January 31, 2001, and accelerated approval from the FDA for the above three indications on May 10, 2001.\n\nGastrointestinal stromal tumor (GIST\nTreatment with adjuvant imatinib following surgical resection of localized Kit-positive GIST\n In locally advanced inoperable patients and metastatic patients, Imatinib is the standard treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16444286",
    "http://www.ncbi.nlm.nih.gov/pubmed/21073206",
    "http://www.ncbi.nlm.nih.gov/pubmed/21464883",
    "http://www.ncbi.nlm.nih.gov/pubmed/12401900",
    "http://www.ncbi.nlm.nih.gov/pubmed/22929880",
    "http://www.ncbi.nlm.nih.gov/pubmed/15671523",
    "http://www.ncbi.nlm.nih.gov/pubmed/17024483",
    "http://www.ncbi.nlm.nih.gov/pubmed/19584824",
    "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
    "http://www.ncbi.nlm.nih.gov/pubmed/20099379",
    "http://www.ncbi.nlm.nih.gov/pubmed/22793867",
    "http://www.ncbi.nlm.nih.gov/pubmed/22363762",
    "http://www.ncbi.nlm.nih.gov/pubmed/20032453",
    "http://www.ncbi.nlm.nih.gov/pubmed/22789835",
    "http://www.ncbi.nlm.nih.gov/pubmed/17033447",
    "http://www.ncbi.nlm.nih.gov/pubmed/20726677"
  ],
  "snippets": [
    {
      "text": "The limited available experience suggests that imatinib could be considered as an individualized treatment approach in severe SSc and underscores the need to identify markers for selecting particular patients, who will safely respond to therapeutic inhibition of tyrosine kinases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22789835",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Dermatofibrosarcoma protuberans (DFSP) is an uncommon cutaneous neoplasm",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21464883",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Moreover, even when surgery is utilized, there are cases where positive margins remain, in which case imatinib would be an option, often in combination with surgery. Imatinib can decrease tumor size preoperatively and help to improve postsurgical aesthetic appearance and minimize functional impairment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21464883",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "for CML we analysed imatinib, dasatinib and nilotinib. RESULTS: Most drugs included in this study had received market authorization in all countries, but the range of indications for which they had been authorized differed by country",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21073206",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Imatinib mesylate, an orally administered kinase inhibitor that targets the Kit (CD117) protein, currently has 10 approved indications including treatment of chronic myelogenous leukemia and metastatic gastrointestinal stromal tumors (GIST). Treatment with adjuvant imatinib following surgical resection of localized Kit-positive GIST, the most recent FDA-approved indication (December 2008), has been shown to significantly improve recurrence-free survival (RFS) compared with surgical resection alone",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726677",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Currently, there are no clinical recommendations regarding how to incorporate imatinib drug plasma monitoring in patients with either chronic myeloid leukemia or gastrointestinal stromal tumors, indications for which imatinib is approved.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20099379",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Imatinib was effective against GIST that were positive for KIT protein",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20032453",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19584824",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "More micro-GIST are discovered with the development of investigations, rising the question of wait and see policy for some of them. In locally advanced inoperable patients and metastatic patients, Imatinib is the standard treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22793867",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The introduction of alternative therapies has challenged well-established indications such as imatinib for chronic myeloid leukaemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16444286",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in (a) chronic phase after failure of IFN-alpha therapy, (b) accelerated phase, and (c) blast crisis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15671523",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Gleevec (imatinib mesylate), a highly promising new drug for the treatment of chronic myelogenous leukemia in blast crisis, in accelerated phase, and in chronic phase after interferon failure or intolerance, received orphan drug status from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development on January 31, 2001, and accelerated approval from the FDA for the above three indications on May 10, 2001.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12401900",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Imatinib is the first effective systemic therapy for advanced GIST.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11831069",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [],
  "exact_answer": "Chronic myelogenous leukemia (CML), Gastrointestinal stromal tumor (GIST), Dermatofibrosarcoma protuberans (DFSP)"
}